Flexion Therapeutics, Inc. (NASDAQ:FLXN)‘s stock had its “buy” rating restated by Laidlaw in a research note issued on Tuesday. They currently have a $38.00 price target on the specialty pharmaceutical company’s stock, up from their prior price target of $35.00. Laidlaw’s price target would indicate a potential upside of 34.56% from the stock’s previous close.

Several other analysts have also recently issued reports on FLXN. Cantor Fitzgerald set a $40.00 target price on Flexion Therapeutics and gave the company a “buy” rating in a research report on Monday, June 12th. ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. BMO Capital Markets reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research report on Tuesday, June 27th. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and set a $44.00 target price on shares of Flexion Therapeutics in a research report on Friday, July 7th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $88.50.

Flexion Therapeutics (FLXN) traded down 2.30% during midday trading on Tuesday, hitting $27.59. The company had a trading volume of 3,210,831 shares. The stock has a 50 day moving average price of $24.85 and a 200 day moving average price of $22.63. Flexion Therapeutics has a 52 week low of $15.93 and a 52 week high of $32.25. The company’s market capitalization is $880.26 million.

Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Equities analysts forecast that Flexion Therapeutics will post ($3.75) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Flexion Therapeutics, Inc. (FLXN) Given “Buy” Rating at Laidlaw” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/10/flexion-therapeutics-inc-flxn-given-buy-rating-at-laidlaw.html.

In other Flexion Therapeutics news, insider Yamo Deniz acquired 3,000 shares of the stock in a transaction dated Friday, September 1st. The stock was purchased at an average price of $24.15 per share, with a total value of $72,450.00. Following the transaction, the insider now directly owns 5,000 shares of the company’s stock, valued at $120,750. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders bought a total of 5,375 shares of company stock valued at $131,575 in the last three months. Insiders own 15.98% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Fiduciary Trust Co. acquired a new stake in shares of Flexion Therapeutics in the 2nd quarter worth $101,000. IFP Advisors Inc boosted its position in shares of Flexion Therapeutics by 24.5% in the 2nd quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after purchasing an additional 1,000 shares in the last quarter. Advisor Group Inc. boosted its position in shares of Flexion Therapeutics by 205.9% in the 2nd quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock worth $105,000 after purchasing an additional 3,500 shares in the last quarter. Voya Investment Management LLC boosted its position in shares of Flexion Therapeutics by 25.8% in the 2nd quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock worth $261,000 after purchasing an additional 2,651 shares in the last quarter. Finally, BB&T Securities LLC acquired a new stake in shares of Flexion Therapeutics in the 2nd quarter worth $289,000. 83.26% of the stock is owned by hedge funds and other institutional investors.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.